Oak Valley (NASDAQ:OVLY) reported quarterly earnings of $0.83 per share. This is a 48.21 percent increase over earnings of $0.56 per share from the same period last year.
AbbVie Announced Provincial Reimbursement for RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan
AbbVie (NYSE: ABBV), today announced that RINVOQ is now listed as a special authorization medication or exception medication status on the formularies of Alberta1, New Brunswick2, Ontario3, Quebec4 and Saskatchewan5 for the treatment of adults with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
